Recursion Pharmaceuticals
clinical target evaluation of sensitization and resistance markers from public pooled screens in the recursion map identification of an unexpected gene similar to identification of novel dual targeting modifier monitor local immune engagement show immune based clearance and associated new target identified for annotated gene a inhibitor measure peripheral inflammation show reduced inflammatory risk potential first in class with enhance anti response | Recursion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
January 2023
Slide
57 of 143
Related slides by other companies
BenevolentAI
Investor Conference
January 2023
the benevolent platform comprehensive data foundations biology hypothesis driven data foundations target identification | BenevolentAI
AbCellera
Investor Presentation
May 2023
drug development has three steps | AbCellera
Alkermes
Investor Day
March 2021
integrated approach to target evaluation and portfolio assessment biology rationale commercial opportunity unmet need high value development candidate regulatory pathway technical feasibility clinical pathway alkermes | Alkermes
Immatics
Investor Presentation
November 2023
unique capability identification of the most relevant target | Immatics
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io